Back HIV/AIDS HIV/AIDS Topics HIV Prevention

AIDS 2014: Good Adherence Seen in IPERGAY Study of Intermittent PrEP

The first results from the IPERGAY study, a trial of pre-exposure prophylaxis (PrEP) in gay men taking place in France and Quebec, Canada, appear to indicate excellent adherence to a novel "pre-and-post" intermittent PrEP strategy designed to save money and reduce time spent taking PrEP unnecessarily. The results were presented at the 20th International AIDS Conference this week in Melbourne, Australia.

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

7/25/14

alt

AIDS 2014: iPrEx OLE Shows PrEP Effectiveness Is 100% for Those Taking 4 or More Doses per Week

iPrEx OLE, the open-label extension of the iPrEx study of pre-exposure prophylaxis (PrEP), reported its main findings this week at the 20th International AIDS Conference in Melbourne, Australia, published simultaneously in The Lancet Infectious Diseases. Overall PrEP effectiveness was 50% overall, but 100% in those taking 4 or more doses per week. There was a substantial early drop-out rate, especially among young people.

alt

Read more:

AIDS 2014: iPrEx OLE Confirms PrEP Works, but Many Don't Take It [VIDEO]

The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly effective among gay men who took it regularly to prevent HIV, but many did not do so, researchers reported this week at the 20th International AIDS Conference in Melbourne.

alt

Read more:

WHO Recommends Pre-Exposure Prophylaxis for Men Who Have Sex with Men

Gay and bisexual men who are at risk for HIV infection should consider using antiretroviral drugs for pre-exposure prophylaxis (PrEP), according to new guidelines from the World Health Organization (WHO), part of a set of recommendations for key populations affected by the HIV/AIDS epidemic.

alt

Read more: